{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BSBHBTNB/2a92fa8a-0439-4ff1-bb14-867b74a5230f/HTML","dcterms:extent":"19 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BSBHBTNB/a9eaa670-afa6-408a-8808-e2ab14403bc0/PDF","dcterms:extent":"68 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BSBHBTNB/27aeb3ff-128c-45ca-bb61-5fe40facf4a4/TEXT","dcterms:extent":"11 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-BSBHBTNB","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2008","dc:creator":"Glaser, Marjana","dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"3 strani"},{"@xml:lang":"sl","#text":"letnik:77"},{"@xml:lang":"sl","#text":"str. I-143-I-145"}],"dc:identifier":["ISSN:1318-0347","COBISSID:2917183","URN:URN:NBN:SI:doc-BSBHBTNB"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"Anemia, Hemolytic, Autoimmune"},{"@xml:lang":"sl","#text":"anemija"},{"@xml:lang":"sl","#text":"Anemija, hemolitična, avtoimunska"},{"@xml:lang":"sl","#text":"bolezen hladnih aglutininov"},{"@xml:lang":"sl","#text":"hematologija"},{"@xml:lang":"sl","#text":"Limfoproliferativne motnje"},{"@xml:lang":"en","#text":"Lymphoproliferative Disorders"},{"@xml:lang":"sl","#text":"rituksimab"},{"@xml:lang":"en","#text":"rituximab"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"Zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Zdravljenje bolezni hladnih aglutininov z rituksimabom| Treatment of cold agglutinin disease with rituximab|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Cold agglutinin disease is an uncommon hemolytic anemia associated sometimes with low-grade B-cell lymphoproliferative disorders. The disease results from increased production of anti erythrocyte antibodies. Standard treatment is mostly unsuccesful. Patient and methods. A 76-years-old patient is presented who was diagnosed with hemolytic anemia caused by cold agglutinins. Later a bone marrow located B cell CD 20 non Hodgkin lymphoma was diagnosed. Standard treatment was unsuccesful, so she received rituximab. After 3 cycles the signs of hemolysis disappeared and the hemoglobin level normalized. The patient is treated every 3 months with rituximab and is in complete remission. Conclusions. Treatment with rituximab is used also for treating immune cytopenias. There are some reports of treating cold agglutinin anemia, where standard treatment is mostly without success. As this is a rare disease only some small studies and case reports have demonstrated the beneficial effect of rituximab on this type of anemia. Despite its high price, rituximab has numerous advantages: immediate and long lasting effect and relatively few side effects"},{"@xml:lang":"sl","#text":"Izhodišča. Bolezen hladnih aglutininov je redka oblika hemolitične anemije, ki je posledica povečanega nastajanja protiteles proti eritrocitom in je izjemoma posledica B-celičnih limfoproliferativnih novotvorb. Standardni načini zdravljenja so večinoma neuspešni. Bolniki in metode. Predstavljena je 76-letna bolnica, pri kateri smo ugotovili hudo hemolitično anemijo s hladnimi aglutinini. Kot vzrok smo našli v kostnem mozgu večje število monoklonskih CD 20 B limfocitov. Ker z običajnim zdravljenjem nismo dosegli uspeha, je prejela rituximab. Že po treh odmerkih so znaki hemolize izginili, koncentracija hemoglobina pa se je popolnoma normalizirala. Bolnica vsake 3 mesece prejema vzdrževalni odmerek rituximaba in je v popolni remisiji. Zaključki. Zdravljenje z rituximabom se vedno bolj uporablja tudi za zdravljenje imunih citopenij. Opisanih je tudi nekaj primerov zdravljenja bolezni hladnih aglutininov, pri katerih sicer s standardnim zdravljenjem večinoma ne dosežemo uspeha. Ker gre za redko bolezen, je le malo študij in le nekaj prikazov primerov, ki so do sedaj dokazali ugoden učinek zdravila pri tej vrsti anemije. Kljub visoki ceni ima rituximab veliko prednosti: hitro in dolgotrajno učinkovanje ter malo stranskih učinkov"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-BSBHBTNB","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-BSBHBTNB"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-BSBHBTNB/a9eaa670-afa6-408a-8808-e2ab14403bc0/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-BSBHBTNB/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-BSBHBTNB"}}}}